Palifermin for management of treatment-induced oral mucositis in cancer patients

Andrei Barasch1, Joel Epstein2, Ken Tilashalski11Department of Diagnostic Sciences, University of Alabama at Birmingham, Birmingham, AL, USA; 2Department of Oral Medicine and Diagnostic Sciences and Otolaryngology/Head and Neck Surgery, University of Illinois at Chicago, Chicago, IL, USAAbstract: Or...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Andrei Barasch, Joel Epstein, Ken Tilashalski
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/210804eb932b46bf916f01e1087f97bc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:210804eb932b46bf916f01e1087f97bc
record_format	dspace
spelling	oai:doaj.org-article:210804eb932b46bf916f01e1087f97bc2021-12-02T01:16:01ZPalifermin for management of treatment-induced oral mucositis in cancer patients1177-54751177-5491https://doaj.org/article/210804eb932b46bf916f01e1087f97bc2009-02-01T00:00:00Zhttp://www.dovepress.com/palifermin-for-management-of-treatment-induced-oral-mucositis-in-cance-a2871https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Andrei Barasch1, Joel Epstein2, Ken Tilashalski11Department of Diagnostic Sciences, University of Alabama at Birmingham, Birmingham, AL, USA; 2Department of Oral Medicine and Diagnostic Sciences and Otolaryngology/Head and Neck Surgery, University of Illinois at Chicago, Chicago, IL, USAAbstract: Oral mucositis (OM) remains a major side effect of various cancer therapies, which exacts a significant price in terms of morbidity and cost of care. Efforts aimed at prevention and/or therapy of OM have been largely unsuccessful. Few agents have shown efficacy, and even those were applicable to limited types of patients. The advent of small-molecule targeted agents opened new possibilities for intervention in the mucopathogenic processes induced by cancer therapies. One of these agents, recombinant human keratinocyte growth factor (KGF), has been studied extensively and has shown promising results in reducing chemotherapy induced OM. This drug&rsquo;s effects on stem cell engraftment, graft-versus-host disease and other treatment-induced morbidities remain undefined. In this article we evaluate the pre-clinical and clinical evidence and discuss the clinical applications of KGF as an adjunct therapeutic agent in oncology.Keywords: mucositis, cancer, therapy, palifermin&nbsp; Andrei BaraschJoel EpsteinKen TilashalskiDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2009, Iss default, Pp 111-116 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Andrei Barasch Joel Epstein Ken Tilashalski Palifermin for management of treatment-induced oral mucositis in cancer patients
description	Andrei Barasch1, Joel Epstein2, Ken Tilashalski11Department of Diagnostic Sciences, University of Alabama at Birmingham, Birmingham, AL, USA; 2Department of Oral Medicine and Diagnostic Sciences and Otolaryngology/Head and Neck Surgery, University of Illinois at Chicago, Chicago, IL, USAAbstract: Oral mucositis (OM) remains a major side effect of various cancer therapies, which exacts a significant price in terms of morbidity and cost of care. Efforts aimed at prevention and/or therapy of OM have been largely unsuccessful. Few agents have shown efficacy, and even those were applicable to limited types of patients. The advent of small-molecule targeted agents opened new possibilities for intervention in the mucopathogenic processes induced by cancer therapies. One of these agents, recombinant human keratinocyte growth factor (KGF), has been studied extensively and has shown promising results in reducing chemotherapy induced OM. This drug&rsquo;s effects on stem cell engraftment, graft-versus-host disease and other treatment-induced morbidities remain undefined. In this article we evaluate the pre-clinical and clinical evidence and discuss the clinical applications of KGF as an adjunct therapeutic agent in oncology.Keywords: mucositis, cancer, therapy, palifermin&nbsp;
format	article
author	Andrei Barasch Joel Epstein Ken Tilashalski
author_facet	Andrei Barasch Joel Epstein Ken Tilashalski
author_sort	Andrei Barasch
title	Palifermin for management of treatment-induced oral mucositis in cancer patients
title_short	Palifermin for management of treatment-induced oral mucositis in cancer patients
title_full	Palifermin for management of treatment-induced oral mucositis in cancer patients
title_fullStr	Palifermin for management of treatment-induced oral mucositis in cancer patients
title_full_unstemmed	Palifermin for management of treatment-induced oral mucositis in cancer patients
title_sort	palifermin for management of treatment-induced oral mucositis in cancer patients
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/210804eb932b46bf916f01e1087f97bc
work_keys_str_mv	AT andreibarasch paliferminformanagementoftreatmentinducedoralmucositisincancerpatients AT joelepstein paliferminformanagementoftreatmentinducedoralmucositisincancerpatients AT kentilashalski paliferminformanagementoftreatmentinducedoralmucositisincancerpatients
_version_	1718403186308415488

Palifermin for management of treatment-induced oral mucositis in cancer patients

Ejemplares similares